Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 3372
  • Home
  • Print this page
  • Email this page

    Article Cited by others

LETTER TO THE EDITOR

Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia

Rishi Pukhraj, Rishi Ekta, Shroff Daraius

Year : 2009| Volume: 57| Issue : 3 | Page no: 241-242

   This article has been cited by
 
1 Idiopathic macular telangiectasia type 2 (idiopathic juxtafoveolar retinal telangiectasis type 2A, Mac Tel 2)
Lihteh Wu,Teodoro Evans,J. Fernando Arevalo
Survey of Ophthalmology. 2013; 58(6): 536
[Pubmed]  [Google Scholar] [DOI]
2 Primitive Retinal Vascular Abnormalities: Tumors and Telangiectasias
Karl Anders Knutsson,Umberto De Benedetto,Giuseppe Querques,Claudia Del Turco,Francesco Bandello,Rosangela Lattanzio
Ophthalmologica. 2012; 228(2): 67
[Pubmed]  [Google Scholar] [DOI]
3 Use of intravitreal bevacizumab injections to treat type 1 idiopathic macular telangiectasia
Byung Gil Moon, Yoon Jeon Kim, Young Hee Yoon, Joo Yong Lee
Graefe s Archive for Clinical and Experimental Ophthalmology. 2011;
[HTML Full text]  [Google Scholar] [DOI]
4 Intravitreal bevacizumab for type 1 idiopathic macular telangiectasia
K Takayama, S Ooto, H Tamura, K Yamashiro, A Otani, A Tsujikawa, N Yoshimura
Eye. 2010; 24(9): 1492
[HTML Full text]  [Google Scholar] [DOI]

 

Read this article